Literature DB >> 8553588

Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107.

M C McIntyre1, M N Ruesch, L A Laimins.   

Abstract

The E6 and E7 proteins of the high-risk human papillomaviruses (HPVs) act coordinately to immortalize human keratinocytes. These viral oncoproteins function by binding and altering the activity of cellular proteins which regulate cell cycle progression. Among the proteins bound by E7 are the retinoblastoma protein, Rb, as well as the related p107 and p130 proteins. In addition, E7 binds cyclin A, which regulates transit through the S and G2/M phases of the cell cycle. In this study, we demonstrate that HPV 18 E7 also associates with cyclin E which controls the G1/S transition. E7/cyclin E complexes were immunoprecipitated from E7-expressing cells as well as from cell extracts using GST-E7 fusion proteins. E7 was found to complex with a single form of cyclin E, and the binding was mediated through p107. Both E7/cyclin E and E7/cyclin A complexes exhibit kinase activity through associated cdk2 proteins which can contribute to phosphorylation of p107. The association of E7 with proteins which regulate transit through the cell cycle may provide an additional mechanism by which infection with human papillomaviruses results in cellular hyperproliferation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8553588     DOI: 10.1006/viro.1996.0008

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  46 in total

1.  Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3.

Authors:  B Mannhardt; S A Weinzimer; M Wagner; M Fiedler; P Cohen; P Jansen-Dürr; W Zwerschke
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates.

Authors:  A Duensing; Y Liu; S A Perdreau; J Kleylein-Sohn; E A Nigg; S Duensing
Journal:  Oncogene       Date:  2007-04-16       Impact factor: 9.867

3.  Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest.

Authors:  Don X Nguyen; Thomas F Westbrook; Dennis J McCance
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Human T-cell leukemia virus type 1 Tax and cell cycle progression: role of cyclin D-cdk and p110Rb.

Authors:  C Neuveut; K G Low; F Maldarelli; I Schmitt; F Majone; R Grassmann; K T Jeang
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

Review 5.  Effect of transforming viruses on molecular mechanisms associated with cancer.

Authors:  Tajhal Dayaram; Susan J Marriott
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

6.  Anchorage-independent transcription of the cyclin A gene induced by the E7 oncoprotein of human papillomavirus type 16.

Authors:  A Schulze; B Mannhardt; K Zerfass-Thome; W Zwerschke; P Jansen-Dürr
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity.

Authors:  M N Ruesch; L A Laimins
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

8.  Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7.

Authors:  Wanxia He; Doug Staples; Clark Smith; Chris Fisher
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  A geminivirus replication protein interacts with a protein kinase and a motor protein that display different expression patterns during plant development and infection.

Authors:  Ling-Jie Kong; Linda Hanley-Bowdoin
Journal:  Plant Cell       Date:  2002-08       Impact factor: 11.277

Review 10.  Impact of Replication Stress in Human Papillomavirus Pathogenesis.

Authors:  Cary A Moody
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.